Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck & Co Expands C Diff Franchise With US Zinplava Approval

Executive Summary

Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.

Advertisement

Related Content

Pfizer To Take Zinplava Rival Into Phase III For C Diff
Merck Sees Decades-Long Time Horizon For Novel Antibiotics
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning
C.Diff Unmet Need Overcomes Bezlotoxumab Panel's Efficacy Concerns
Summit's Antibiotic Spares The Microbiome And Spoils The C Diff Rods

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel